Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News NurExone Biologic Inc. NRXBF


Primary Symbol: V.NRX

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:NRX)

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

GlobeNewswire 3 days ago

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

GlobeNewswire April 25, 2024

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

GlobeNewswire April 19, 2024

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

GlobeNewswire April 2, 2024

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

GlobeNewswire March 27, 2024

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

GlobeNewswire March 22, 2024

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

GlobeNewswire March 15, 2024

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

GlobeNewswire March 8, 2024

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

GlobeNewswire March 1, 2024
View More News ››

Opinion & Analysis (TSXV:NRX)

ExoTherapy offers hope for treating acute spinal cord injuries

Brieanna McCutcheon  September 19, 2023
View More Opinion ››

Bullboard Posts (TSXV:NRX)

2.5 years to break even for this company

thats a long wait for a maybe....this one is for patient speculators only.....no quick trade flip here....go try those meme stocks for a...
88guy88 - 7 days ago

Wait for 41 cents

looks like it wants to head back to the 200 day moving average which is 41 cents....no news or results for a long time while they do...
88guy88 - 8 days ago

100,000 shares are for sale at 63 cents

only a few thousand shares on the offers in the 50s.....here we go!
88guy88 - May 3, 2024

NurExone Unlocks Several Milestones Since March 2024

NurExone Unlocks Several Milestones Since March 2024 (TSXV: NRX, FSE: J90, NRX.V) ...
Mathew177 - April 19, 2024

This one is a thin trader and no buyer interest

did not hold the 60 cent level ....so likely down she goes.....no news to move it up and establishing a home base in Israel is probably...
88guy88 - April 16, 2024

Price is below the 20 and 50 day average of 70 cents

the 200 day average support is at 38 cents......appears to be bouncing of the 60 cent base but if it falls below that 60....look out...
88guy88 - April 12, 2024
View more Bullboard ››

Lode Gold Resources Inc

Lode Gold Resources Inc

Lode Gold Resources Inc. is a Canadian exploration and development company with grassroots and advanced exploration ...
View More »